Top

Published in:

01-08-2015 | Editorial

Diabetologia at 50: celebrating half a century of progress in diabetes research and care

Author: Juleen R. Zierath

Published in: Diabetologia | Issue 8/2015

Excerpt

The colourful cover of this issue of Diabetologia celebrates our prestigious journal’s golden anniversary—50 years publishing ground-breaking diabetes research, both basic and clinical and from all over the world. …

Schuit F (2015) Comparative genomics: beyond the horizon of the next research grant. Diabetologia. doi:10.1007/s00125-015-3620-x PubMed

Russell NDF, Cooper ME (2015) 50 years forward: mechanisms of hyperglycaemia-driven diabetic complications. Diabetologia. doi:10.1007/s00125-015-3600-1

McCarthy MI (2015) Genomic medicine at the heart of diabetes management. Diabetologia. doi:10.1007/s00125-015-3588-6 PubMedCentral

Booth FW, Hawley JA (2015) The erosion of physical activity in Western societies: an economic death march. Diabetologia. doi:10.1007/s00125-015-3617-5 PubMed

Schrauwen P, van Marken Lichtenbelt WD, Spiegelman BM (2015) The future of brown adipose tissues in the treatment of type 2 diabetes. Diabetologia. doi:10.1007/s00125-015-3611-y

Iroz A, Couty J-P, Postic C (2015) Hepatokines: unlocking the multi-organ network in metabolic diseases. Diabetologia doi:10.1007/s00125-015-3634-4

Schalkwijk CG (2015) Vascular AGE-ing by methylglyoxal: the past, the present and the future. Diabetologia. doi:10.1007/s00125-015-3597-5 PubMedCentral

Roden M (2015) Future of muscle research in diabetes: a look into the crystal ball. Diabetologia. doi:10.1007/s00125-015-3629-1

Halban PA (2015) 50 years forward: beta cells. Diabetologia. doi:10.1007/s00125-015-3601-0 PubMed

10.

Kahn SE, Buse JB (2015) Medications for type 2 diabetes: how will we be treating patients in 50 years? Diabetologia. doi:10.1007/s00125-015-3541-8 PubMed

11.

Ahrén B (2015) Creative use of novel glucose-lowering drugs for type 2 diabetes: where will we head in the next 50 years? Diabetologia. doi:10.1007/s00125-015-3557-0

12.

Meier JJ, Nauck MA (2015) Incretin-based therapies: where will we be 50 years from now? Diabetologia. doi:10.1007/s00125-015-3608-6

Title: Diabetologia at 50: celebrating half a century of progress in diabetes research and care
Author: Juleen R. Zierath
Publication date: 01-08-2015
Publisher: Springer Berlin Heidelberg
Published in: Diabetologia / Issue 8/2015
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI: https://doi.org/10.1007/s00125-015-3640-6

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 8/2015

Incretin-based therapies: where will we be 50 years from now?

Oncostatin M is a potential agent for the treatment of obesity and related metabolic disorders: a study in mice

Variable effects of statins on glucose homeostasis parameters and their diabetogenic role. Reply to Kostapanos MS, Agouridis AP and Elisaf MS [letter]

GIP increases adipose tissue expression and blood levels of MCP-1 in humans and links high energy diets to inflammation: a randomised trial

Prospective association of a genetic risk score and lifestyle intervention with cardiovascular morbidity and mortality among individuals with type 2 diabetes: the Look AHEAD randomised controlled trial

Delta cell death in the islet of Langerhans and the progression from normal glucose tolerance to type 2 diabetes in non-human primates (baboon, Papio hamadryas)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials